Home/Pipeline/Relacorilant + Enzalutamide

Relacorilant + Enzalutamide

Prostate Cancer

Phase 2Active (Investigator-Sponsored)

Key Facts

Indication

Prostate Cancer

Phase

Phase 2

Status

Active (Investigator-Sponsored)

Company

Corcept Therapeutics

About Corcept Therapeutics

Corcept Therapeutics has successfully transitioned from a research entity to a fully integrated commercial organization, anchored by its FDA-approved product Korlym® for hypercortisolism. Its core strategy leverages a proprietary platform of selective cortisol modulators, recently validated by the FDA approval of relacorilant (Lifyorli®) for platinum-resistant ovarian cancer. With over 30 ongoing studies across endocrinology, oncology, metabolism, and neurology, Corcept is pursuing a focused, independent path to expand the therapeutic reach of its unique mechanism.

View full company profile

Therapeutic Areas

Endocrinology Oncology Metabolism Neurology

Other Prostate Cancer Drugs

Drug	Company	Phase	Status
APVO442	Aptevo Therapeutics	Preclinical	Active
APVO452	Aptevo Therapeutics	Discovery	Active
BIO 300	Humanetics Corp.	Not Specified	Active
Opaganib	RedHill Biopharma	Phase 2	Active
MagSense™ PSMA Imaging Agent	Imagion Biosystems	Pre‑clinical	Active
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
Leronlimab	CytoDyn	Preclinical	Phase in progress
CROES Registry	AngioDynamics	Post-Market Registry	Active
Cannabics® PRST-33	CNBX Pharmaceuticals	Discovery	In vitro POC
HDP-103	Heidelberg Pharma	Preclinical	Active
ENV105	Kairos Pharma	Phase 2	Active
AI for Prostate Cancer	Invenio Imaging	Research	Active